News
Eli Lilly's baricitinib showed in the phase 3 BRAVE - AA - PEDS trial that nearly complete scalp hair regrowth can be achieved in adolescents with severe alopecia after one year of treatment
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments